Chie Aoki1, Yutaka Inaba2, Hyonmin Choe1, Utako Kaneko1, Ryoki Hara1, Takako Miyamae1, Tomoyuki Imagawa1, Masaaki Mori1, Mari S Oba1, Shumpei Yokota1, Tomoyuki Saito1. 1. From the Department of Orthopedic Surgery, the Department of Pediatrics, and the Department of Biostatistics and Epidemiology, Yokohama City University, Yokohama, Japan.C. Aoki, MD; Y. Inaba, MD, PhD, Associate Professor; H. Choe, MD, PhD, Department of Orthopedic Surgery; U. Kaneko, MD; R. Hara, MD, PhD; T. Miyamae, MD, PhD; T. Imagawa, MD, PhD; M. Mori, MD, PhD, Associate Professor, Department of Pediatrics; M.S. Oba, Department of Biostatistics and Epidemiology; S. Yokota, MD, Professor of Pediatrics, Department of Pediatrics; T. Saito, MD, Professor of Orthopedics, Department of Orthopedic Surgery, Yokohama City University. 2. From the Department of Orthopedic Surgery, the Department of Pediatrics, and the Department of Biostatistics and Epidemiology, Yokohama City University, Yokohama, Japan.C. Aoki, MD; Y. Inaba, MD, PhD, Associate Professor; H. Choe, MD, PhD, Department of Orthopedic Surgery; U. Kaneko, MD; R. Hara, MD, PhD; T. Miyamae, MD, PhD; T. Imagawa, MD, PhD; M. Mori, MD, PhD, Associate Professor, Department of Pediatrics; M.S. Oba, Department of Biostatistics and Epidemiology; S. Yokota, MD, Professor of Pediatrics, Department of Pediatrics; T. Saito, MD, Professor of Orthopedics, Department of Orthopedic Surgery, Yokohama City University. yute0131@med.yokohama-cu.ac.jp.
Abstract
OBJECTIVE: Tocilizumab (TCZ), an antiinterleukin-6 receptor monoclonal antibody, is clinically beneficial in patients with systemic-onset juvenile idiopathic arthritis (sJIA). We investigated the clinical and radiological outcomes of TCZ therapy in patients with sJIA. METHODS: We retrospectively evaluated 2 clinical trials (NCT00144599 and NCT00144612) involving 40 patients with sJIA who received intravenous TCZ (8 mg/kg) every 2 weeks. Clinical data and radiographs of the hands and large joints were assessed before and during TCZ treatment. The Poznanski score, modified Larsen scores of the hands and large joints, and Childhood Arthritis Radiographic Score of the Hip (CARSH) were recorded. RESULTS: After a mean duration of 4.5 years of TCZ treatment, clinical data had improved significantly, the mean Poznanski score improved from -1.5 to -1.1, the mean Larsen score of the hands deteriorated from 7.0 to 10.0, the mean Larsen score for the large joints deteriorated from 5.9 to 6.8, and the CARSH worsened from 3.9 to 6.2. The Larsen score for the large joints improved in 11 cases (28%), remained unchanged in 8 cases (20%), and worsened in 21 cases (52%). Matrix metalloproteinase 3 (MMP-3) levels remained significantly higher (278 mg/dl) in patients with worsened Larsen scores than in patients with improved or unchanged scores (65 mg/dl). Logistic regression analysis showed that older age at disease onset was a significant risk factor for radiographic progression. CONCLUSION: The modified Larsen score of the large joints deteriorated in half the patients who had high MMP-3 levels during TCZ treatment and who were significantly older at disease onset.
OBJECTIVE:Tocilizumab (TCZ), an antiinterleukin-6 receptor monoclonal antibody, is clinically beneficial in patients with systemic-onset juvenile idiopathic arthritis (sJIA). We investigated the clinical and radiological outcomes of TCZ therapy in patients with sJIA. METHODS: We retrospectively evaluated 2 clinical trials (NCT00144599 and NCT00144612) involving 40 patients with sJIA who received intravenous TCZ (8 mg/kg) every 2 weeks. Clinical data and radiographs of the hands and large joints were assessed before and during TCZ treatment. The Poznanski score, modified Larsen scores of the hands and large joints, and Childhood Arthritis Radiographic Score of the Hip (CARSH) were recorded. RESULTS: After a mean duration of 4.5 years of TCZ treatment, clinical data had improved significantly, the mean Poznanski score improved from -1.5 to -1.1, the mean Larsen score of the hands deteriorated from 7.0 to 10.0, the mean Larsen score for the large joints deteriorated from 5.9 to 6.8, and the CARSH worsened from 3.9 to 6.2. The Larsen score for the large joints improved in 11 cases (28%), remained unchanged in 8 cases (20%), and worsened in 21 cases (52%). Matrix metalloproteinase 3 (MMP-3) levels remained significantly higher (278 mg/dl) in patients with worsened Larsen scores than in patients with improved or unchanged scores (65 mg/dl). Logistic regression analysis showed that older age at disease onset was a significant risk factor for radiographic progression. CONCLUSION: The modified Larsen score of the large joints deteriorated in half the patients who had high MMP-3 levels during TCZ treatment and who were significantly older at disease onset.
Authors: Anne M Selvaag; Eva Kirkhus; Lena Törnqvist; Vibke Lilleby; Hanne A Aulie; Berit Flatø Journal: Pediatr Rheumatol Online J Date: 2017-04-11 Impact factor: 3.054
Authors: P C E Hissink Muller; W G van Braak; D Schreurs; C M Nusman; S A Bergstra; R Hemke; D Schonenberg-Meinema; J M van den Berg; T W Kuijpers; Y Koopman-Keemink; M A J van Rossum; L W A van Suijlekom-Smit; D M C Brinkman; C F Allaart; R Ten Cate; M Maas Journal: Pediatr Rheumatol Online J Date: 2019-09-04 Impact factor: 3.054
Authors: Heshuang Qu; Erik Sundberg; Cecilia Aulin; Manoj Neog; Karin Palmblad; Anna Carin Horne; Fredrik Granath; Alexandra Ek; Erik Melén; Mia Olsson; Helena Erlandsson Harris Journal: Pediatr Rheumatol Online J Date: 2021-12-28 Impact factor: 3.054